Research Priorities for Inpatient General Paediatrics in Australia and New Zealand: A Modified Delphi Study

Davina Buntsma1, Sarah McNab1,2,3, Jessica C Costa-Pinto4,5

  • 1Department of General Medicine, The Royal Children's Hospital, Melbourne, Australia.

Insights

This study identified top research priorities for Australian and New Zealand children

Area of Science:

  • Pediatric Research
  • Inpatient Care
  • Health Priorities

Background:

  • General paediatrics inpatient research requires clear priorities.
  • Establishing consensus is crucial for effective resource allocation.

Purpose of the Study:

  • To develop consensus on research priorities for multi-centre, inpatient general paediatrics in Australia and New Zealand.
  • To guide future research collaborations and funding.

Main Methods:

  • A three-stage modified Delphi study was conducted by the Children's Inpatient Research Collaboration of Australia and New Zealand (CIRCAN).
  • Anonymous surveys and the Hanlon Process of Prioritisation were used to refine and rank research questions.
  • Participants included paediatricians, trainees, nursing, allied health staff, and academics.

Main Results:

  • 19 priority research questions were identified through the Delphi process.
  • Respiratory conditions, including asthma and bronchiolitis, were the highest-ranked research topics.
  • Sepsis/meningitis, cellulitis, eating disorders, rehabilitation, and complex care coordination were also identified.

Conclusions:

  • A consensus list of priority research questions for inpatient general paediatrics was established.
  • Respiratory conditions emerged as the most highly ranked research area.
  • These findings will inform and direct future multicentre research in Australian and New Zealand paediatrics.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
383
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
786
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
489
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
346